AstraZeneca - Research-Based BioPharmaceutical Company

Spotlighting our latest science in chronic kidney disease at two major global congresses in June: ADA and ERA-EDTA

Learn more

We believe in what science can do

What drives you today?

Ground-breaking science

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Director, Bioinformatics and Data Science, Research and Early Development, Oncology R&D

Go to our current Bioinformatics jobs

Publications

Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.

View our publications

We have

157

projects in our pipeline

View pipeline

Acoustic mass spectrometer platform

Explore our technology

Our Gaithersburg site (US) is one of AstraZeneca's three global strategic science centres

Explore all our science centres

Corporate Press Release

Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer

18 June 2019

Corporate Press Release

Calquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia

17 June 2019

Our science

At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

Find out more

Career opportunities

There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it.
Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development

Go to our current Bioinformatics jobs

Acoustic mass spectrometer platform

Explore our technology

Three

strategic science centres

Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries

Find our about our science

Inhibiting stages in the DNA damage response pathway

Our focus areas

Cardiovascular and Metabolic diseases

Oncology

Respiratory

Inflammation and autoimmunity

Neuroscience

Infection and Vaccines

AstraZeneca job search

At AstraZeneca we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.

Search for a job now

Start a career that will help improve life for millions.

Learn more about our School/College Student, Undergraduate, Graduate and Post Doctorate programmes with us in our Early Careers page.

Find your early career now

Working at AstraZeneca

We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. Find out more about our teams and the work they do.

Find out more on the careers section

To partner with AstraZeneca

I often say being in Business Development is having the best job in AstraZeneca in terms of the motivation, interest and challenging work we do with incredibly smart people from science and business on projects that really make a difference for our partners and patients.
Shaun Grady, Vice-President Business Development Operations

See our partnering contacts

Horizon Discovery and AstraZeneca: searching for novel, personalised cancer therapies

See more partnering case studies

Partnering with us

We partner with like-minded organisations and pursue a range of different types of opportunities that are aligned with our portfolio and areas of expertise.

Learn more about our areas of interest

Open Innovation

Our Open Innovation platform is designed to foster open innovation partnerships spanning all stages of drug discovery and development.

Learn more on the Open Innovation site

Corporate Press Release

Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer

18 June 2019

Corporate Press Release

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer, a population with high unmet need

8 May 2019

Collaborate with us

The best science doesn't happen in isolation.

Visit our partnering section

Investor information

“Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. In Oncology, Tagrisso, Imfinzi and Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta and Fasenra also grew strongly. Emerging Markets, our largest sales region, delivered an outstanding performance with a 22% growth rate; all of its sub-regions grew strongly, including China at 28%.
Pascal Soriot, Executive Director and Chief Executive Officer

Meet our people